✉news HealthFitness first seen 1 d ago, last 1 d ago, peak #26
CSL signs drug deal with Swiss biotech giant on rare disease
Original: ASX CSL: CSL signs drug deal with Swiss biotech giant to fight rare disease
Australian biotech CSL has signed a deal with a major Swiss pharmaceutical company to develop a treatment for a rare disease, according to the Australian Financial Review. The agreement, reported for ASX-listed CSL, marks another step in the company's push to expand its pipeline beyond its core plasma and vaccine businesses. Details of the partner, the disease and financial terms were not disclosed in the initial report.
Why now: Investors are watching CSL's licensing and partnership activity for signs of pipeline growth affecting the ASX-listed stock.
Evidence
API: https://socialmediatrends-api.osmike.com/v1/trends/1045655